BDXHealthcare · Medical Instruments & SuppliesThe 14 Wall Street analysts covering Becton, Dickinson & Co. hold a median 12-month price target of $193 — +6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 17 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Becton, Dickinson & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Growth (40): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +6.5% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | RBC Capital | Maintains | Sector Perform | $180 → $190 |
| 7 Aug 2026 | Citigroup | Maintains | Buy | $198 → $204 |
| 7 Aug 2026 | Piper Sandler | Maintains | Neutral | $161 → $175 |
| 7 Aug 2026 | RBC Capital | Maintains | Sector Perform | $175 → $180 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $161 → $170 |
| 5 Aug 2026 | TD Cowen | Maintains | Hold | — |
| 5 Aug 2026 | TD Cowen | Maintains | Hold | $163 → $182 |
| 28 July 2026 | UBS | Initiates | Buy | — |
| 28 July 2026 | UBS | Initiates | Buy | $190 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $190 → $180 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 11 May 2026 | Barclays | Maintains | Overweight | — |
| 8 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 4 May 2026 | TD Cowen | Maintains | Hold | — |
| 17 Apr 2026 | Piper Sandler | Maintains | Neutral | — |
| 10 Apr 2026 | Goldman Sachs | Reinstates | Neutral | $167 |
| 26 Mar 2026 | Piper Sandler | Maintains | Neutral | — |
| 23 Mar 2026 | Argus Research | Maintains | Buy | — |
| 11 Feb 2026 | Barclays | Reinstates | Overweight | $202 |
| 11 Feb 2026 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BDX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 26% of US stocks
Cheaper than 51% of US stocks
Cheaper than 46% of US stocks
Cheaper than 36% of US stocks
Higher than 40% of US stocks
Higher than 14% of US stocks
Higher than 58% of US stocks
Higher than 73% of US stocks
Higher than 58% of US stocks
Higher than 56% of US stocks
Higher than 73% of US stocks
Higher than 52% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Becton, Dickinson & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BD announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8, while Jeff Silvestri is set to retire. The appointment was announced on August 17, 2026.
Why it matters — A change in a senior quality leadership role is relevant to BDX watchers as it signals a transition in the company's executive team overseeing quality operations.
Becton, Dickinson and Company (BDX) was one of four Dividend Kings that reported earnings last week, according to Zacks Investment Research.
Why it matters — BDX watchers closely track earnings reports from Dividend Kings because these companies have lengthy track records of consistent dividend growth.
Seeking Alpha reiterated its buy rating on Becton Dickinson, citing the company's diverse and growing clinical portfolio, a favorable Fitch rating that lowers balance-sheet risk, and improving market performance versus the S&P 500.
Why it matters — BDX watchers would note the reaffirmed buy rating and favorable credit rating as signals of continued confidence in the company's clinical portfolio and financial stability.
BD announced completion of enrollment in the PREVENT clinical trial, the first large-scale randomized study evaluating Phasix™ Mesh for the prevention of incisional hernias following abdominal surgery. The company described this as a significant milestone in its advanced tissue regeneration strategy and expansion efforts.
Why it matters — The milestone signals progress in BD's advanced tissue regeneration pipeline aimed at addressing an unmet need in hernia prevention, relevant to its broader growth strategy.
About a year ago, 24/7 Wall Street identified four overlooked Dividend Aristocrats as potential growth plays among income names. The publication has now reviewed how those picks performed and introduced three new Dividend Aristocrat picks.
Why it matters — BDX, as a Dividend Aristocrat, may be among the income names being evaluated and selected in this recurring coverage that BDX watchers follow.
The 14 Wall Street analysts covering Becton, Dickinson & Co. have a median 12-month price target of $193, with estimates ranging from $170 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Becton, Dickinson & Co., 7 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Becton, Dickinson & Co. 92 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Aug 2026, Becton, Dickinson & Co. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +6.5% from the last close, and Ticker Nerd's factor model ranks Becton, Dickinson & Co. 92 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Becton, Dickinson & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $170 to $225 over the next 12 months.
Becton, Dickinson & Co. returned +21.1% over the 12 months to 18 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare systems and research institutions worldwide. Its portfolio includes medical surgical products such as needles, syringes, and sharps-disposal units, as well as prefilled drug delivery systems that support medication administration in clinical and home-care settings.
The most recent item we track (PRNewsWire, 17 Aug 2026): "BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire". BD announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8, while Jeff Silvestri is set to retire. The appointment was announced on August 17, 2026.
Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare systems and research institutions worldwide. Its portfolio includes medical surgical products such as needles, syringes, and sharps-disposal units, as well as prefilled drug delivery systems that support medication administration in clinical and home-care settings. In diagnostics and life sciences, the company provides instruments, reagents, and systems used for specimen collection, infectious disease testing, and advanced cell analysis, including flow cytometry and cell-imaging platforms. Becton, Dickinson and Company operates through distinct business segments that address medication management, life science research, and interventional therapies, serving hospitals, clinics, laboratories, and biopharmaceutical companies. Headquartered in Franklin Lakes, New Jersey, and founded in 1897, it plays a significant role in supporting healthcare delivery and laboratory workflows across both developed and emerging markets.
CEO Mr. Thomas E. Polen Jr. · 72,000 employees · United States · https://www.bd.com